MEDx Translational

MEDx Translational Medicine, formerly known as QIAGEN (Suzhou) Translational Medicine Co., Ltd., was established in 2013 and operates as a provider of companion diagnostics and translational medicine solutions for precision medicine in China. The company provides integrated solutions that cover biomarker discovery, target validation, molecular testing, and patient stratification to support drug clinical trials and the research, development, and commercialization of in-vitro diagnostics (IVD) and companion diagnostics (CDx).

MEDx utilizes comprehensive translational platforms, including genomics, proteomics, cytomics, and pathology, to serve its clients. The firm offers diagnostic solutions for solid tumors and hematological malignancies through assays based on immunohistochemistry (IHC), polymerase chain reaction (PCR), and next-generation sequencing (NGS) technologies. The company collaborates with pharmaceutical companies to advance precision medicine. In 2021, MEDx extended a strategic partnership with Abcam to co-develop and commercialize companion and in-vitro diagnostic kits for the Chinese market. The company is also a founding member of the China Precision Medicine and Companion Diagnosis Committee, part of the Chinese Society of Biotechnology.

The company's history includes a joint venture with QIAGEN N.V. in 2013 and securing strategic investors such as Simcere Pharma and Shanghai Anjie Medical Equipment Co., Ltd. It has received multiple certifications, including China CNAS, ISO17025, CAP accreditation, and ISO 13485. Keywords: precision medicine, companion diagnostics, translational medicine, biomarker discovery, target validation, molecular testing, patient stratification, drug clinical trials, IVD, CDx, genomics, proteomics, cytomics, pathology, solid tumors, hematological malignancies, next-generation sequencing, clinical development, life sciences